2. Signaling Pathways
  3. Neuronal Signaling
  4. CaMK
  5. CaMK III/eEF-2K Isoform

CaMK III/eEF-2K

CaMK III/eEF-2K is a calcium/calmodulin-regulated atypical α-kinase that phosphorylates eEF-2 and impedes translation elongation, thereby reducing global protein synthesis[1][2]. Mechanistically, Ca2+/calmodulin activates eEF-2K autophosphorylation at Thr-348 and Ser-500, which regulates substrate phosphorylation and calcium dependence[3]. Upstream mTOR and MAPK pathways negatively regulate eEF-2K activity, linking nutrient and growth signaling to translational control[2]. In cancer models, eEF-2K regulates autophagy, apoptosis, angiogenesis, invasion, and metastasis, and supports tumor-cell adaptation to hypoxia, nutrient depletion, and acidosis[4]. In Akt-inhibited glioma cells, eEF-2K inhibition suppresses autophagy, promotes apoptosis, and reinforces MK-2206 efficacy[5]. Compared with conventional protein kinases and related CaMK signaling enzymes, eEF-2K is distinguished as an atypical α-kinase and the only calmodulin-dependent member of this family[1][4]. For experimental applications, recombinant human eEF-2K can be purified from E. coli and phosphorylates wheat-germ eEF-2 with kinetic parameters comparable to mammalian enzyme[2]. Small-molecule and natural-product eEF-2K inhibitors provide tools for cancer chemotherapy research and structure-activity relationship studies[4].

CaMK III/eEF-2K Related Products (2):

Cat. No. Product Name Effect Purity
  • HY-146324
    PROTAC eEF2K degrader-1
    		98.64%
    PROTAC eEF2K degrader-1 (Compound 11l) is an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells. PROTAC eEF2K degrader-1 mediates eEF2K degradation.
  • HY-181506
    TYMJ-01
    		Degrader
    TYMJ-01 is a fluorescent probe and eEF2K degrader. TYMJ-01 induces dose-dependent and specific degradation of eEF2K via the ubiquitin-proteasome pathway, with a DC50 of 82 nM. TYMJ-01 inhibits the proliferation, migration and invasion of triple-negative breast cancer cells. TYMJ-01 enables dynamic fluorescent imaging of eEF2K degradation in triple-negative breast cancer cells; it enhances the anti-tumor activity of Paclitaxel (HY-B0015). TYMJ-01 can be used for the research of triple-negative breast cancer.